Table 3 Common characteristics of patients receiving or not receiving baricitinib in the propensity score–matched populations from the University of Pisa and the Albacete Hospital.

PS, propensity score matching. All data are means (SD) or number of participants (%).

Baricitinib group
(n = 83)
PS control
group (n = 83)
Age74.0 (12.5)74.1 (13.6)
Male sex43 (51.8)42 (50.6)
Coexisting conditions
  Hypertension50 (60.2)53 (63.9)
  Cardiovascular disease27 (32.5)21 (25.3)
  Solid cancer8 (9.6)10 (12.0)
  Diabetes28 (33.7)22 (26.5)
  COPD12 (14.5)12 (14.5)
  Chronic kidney failure7 (8.4)7 (8.4)
Charlson comorbidity index2.7 (2.3)2.8 (2.7)
Medications at baseline
  ACE inhibitor or ARB33 (39.8)35 (42.2)
Baseline PaO2/FiO2268 (101)266 (86)
Baseline laboratory tests
  C-reactive protein (mg/liter)86.0 (100.6)82.2 (123.9)
  Lymphocyte count (per μl)1052 (831)40 (46)
  ALT (U/liter)38.7 (26.5)34.6(29.9)
Concomitant treatment
  Hydroxychloroquine79 (95.2)80 (96.4)
  Antibiotics79 (95.2)79 (95.2)
  Lopinavir/ritonavir69 (83.1)71 (85.5)
  LMWH82 (98.8)82 (98.8)
  Glucocorticoids71(85.5)70 (84.3)
Primary outcome14 (16.9)*29 (34.9)*
Time to outcome19.9 (9.1)**13.1 (9.7)**

*P < 0.01

**P < 0.001